Efficacy of CeraVe® Moisturizing Cream on Skin Pruritus in Elderly Patients

Sponsored by Shanghai Zhongshan Hospital

About this trial

Last updated 3 years ago

Study ID

B2023-004

Status

Unknown

Type

Interventional

Phase

N/A

Placebo

Accepting

60+ Years

All Sexes

Trial Timing

Ended 2 years ago

What is this trial about?

The goal of this clinical trial is to evaluate the CeraVe® moisturizing cream's efficiency on the improvement of skin barrier in patients with chronic elderly pruritus. The main questions it aims to answer are: type of study: clinical trial participant population:in patients with chronic elderly pruritus [question 1] Evaluate the CeraVe® moisturizing cream's efficiency on the improvement of skin barrier in patients with chronic elderly pruritus, including improvements of redness, dryness/squamation, itching, burning, tingling, tightness and other factors. [question 2] Evaluate the tolerance of CeraVe® Moisturising Cream. [question 3] Evaluate the product experience of patients who were utilizing CeraVe® Moisturising Cream. This trial utilizing simple randomization, the left and right calves of paticipants were randomly divided into test side(applicating CeraVe® Moisturising Cream ) and control side (applicating Standard Cream)according to random number representation. Grouping results were double-blinded.

What are the participation requirements?

Inclusion Criteria

* patients age≥60 years old(male or female).

* Clinician evaluates dry pruritus or patient complains of pruritus, which lasts for more than 1 month.

* Patients informed consent to the purpose and content of the research, willing to cooperate with follow-up observation. Have good communication and understanding skills.

* Patients are willing to share photos for medical research purpose.

Exclusion Criteria

* Patients with bacterial and/or viral infections in the acute phase of skin inflammation

* The affected area is complicated by other skin diseases that may affect the efficacy evaluation

* Those who are allergic to the ingredients of this product or with allergic constitution

* Patients who have severe heart, brain, lung, or liver damage.

* Those who have received systemic or local antiallergic drug treatment within 2 weeks before enrollment of this study.

* Those who attending other clinical drug trials within 4 weeks before enrollment of this study.

* Patients with a history of alcohol or drug abuse.

* Patients who are unwilling to sign the informed consent form, and those who are unwilling to cooperate.